Zai Lab Ltd ZLAB
Deals with insiders in the proxy filed Apr 28, 2026
Proxy, Item 404Deals between ZLAB and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement.
New this year
Compared with Apr 29, 2025
Paragraphs about a deal, a person or a relative with nothing like them in the proxy filed Apr 29, 2025.
Transactions with Related Persons“In January 2025, the Company entered into a license agreement with Zenas BioPharma (HK) Limited, a subsidiary of Zenas BioPharma, Inc. (“Zenas”), pursuant to which the Company obtained a license under certain patents and know-how of Zenas to develop and commercialize products containing a differentiated humanized monoclonal antibody targeting IGF-1R as an active ingredient in Greater China. One of the members of the Company’s Board of Directors, Mr. Moulder, is also the Chief Executive Officer and Chairman of the Board of Directors of Zenas. Since January 2025, the Company has paid a $10.0 million upfront fee in accordance with this agreement. As of March 31, 2026, the Company may be required to pay an additional aggregate amount of up to $117.0 million in development and sales-based milestones as well as certain royalties at tiered percentage rates ranging from high-single digits to mid-teens on annual net sales of the licensed products in the licensed territories. The related party arrangement with Zenas was approved by the Board of Directors in accordance with our related party transaction policy, excluding Mr. Moulder pursuant to our conflicts of interest policy. This related party transaction is not a connected transaction under Chapter 14A of the HK Listing Rules.”
Read it in the proxyopen_in_new
No longer reported 2 paragraphs of the proxy filed Apr 29, 2025 with nothing like them this year
Transactions with Related Persons“The following transactions require disclosure in this proxy statement pursuant to Regulation S-K Item 404(a). We believe that the transactions described below were made on terms no less favorable to us than could have been obtained from unaffiliated third parties.”
Read it in last year's proxyopen_in_new
Transactions with Related Persons“MEDx (Suzhou) Translational Medicine Co., Ltd. (MEDx) provides product research and development services to the Company. We paid MEDx approximately $25,000 for services rendered in 2024 and nil for January 1 to April 1, 2025. Mr. Zhang, the Founder, Chief Executive Officer, and member of the Board of Directors of MEDx is an immediate family member of Dr. Samantha (Ying) Du, our Founder, Chief Executive Officer, and Chairperson of the Board of Directors. The related party arrangement with MEDx was approved by the Audit Committee in accordance with our related party transaction policy.”
Read it in last year's proxyopen_in_new
The whole section
As filed
17 paragraphs quoted as filed
Review and Approval of Transactions with Related Parties“The Audit Committee has adopted a written policy and procedures for review and approval or ratification of transactions involving the Company and related parties, including executive officers, directors, beneficial owners of more than ten percent of our voting securities, and immediate family members or certain related entities of such persons. The policy covers any related party transaction that meets the minimum threshold for disclosure in this proxy statement under relevant SEC rules, which generally include transactions involving amounts exceeding $120,000 in which a related party has a direct or indirect material interest.”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Parties“Pursuant to the related party transaction policy and procedures, management determines whether a transaction requires review by the Audit Committee, in which case the transaction, along with all material information, will be provided to the Audit Committee for review, approval, ratification, or termination. The Audit Committee will review the material terms and relevant factors to determine whether the transaction would be on an arms’ length basis and in the ordinary course of business. Subject to certain exceptions, related party transactions must be pre-approved by the Audit Committee, Board of Directors, or shareholders, as described below:”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Parties“Audit Committee: Approval of the Audit Committee is required for all related party transactions, other than the exceptions described below.”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Parties“If prior Audit Committee approval is not feasible, the Audit Committee will consider the transaction and determine whether to ratify the transaction at its next regularly scheduled meeting. In the event that a related party transaction was not previously approved or ratified under this policy, the Chair of the Audit Committee will be notified promptly. The Audit Committee or, if it is not practicable for the entire Audit Committee to consider the matter, the Chair of the Audit Committee, will consider whether the related party transaction should be ratified or rescinded or other action be taken.”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Parties“Board of Directors: The Board of Directors will determine whether to approve the transactions if: (1) the transactions would not be in the ordinary course of business or on an arms’ length basis or (2) the amount, individually or in the aggregate, would exceed the lesser of (i) 1% of annual consolidated operating expenses per the last audited annual financial statements and (ii) $1,000,000.”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Parties“Shareholders: If the Board of Directors determines that a related party transaction should be brought before the Company’s shareholders, then approval of such related party transaction shall be presented to the shareholders for approval through a resolution at a general meeting of shareholders or pursuant to any other method consistent with applicable law.”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Parties“No director will participate in any communication, discussion, or decision with respect to a transaction for which he or she is a related party, other than to provide all material information concerning the related party transaction to the Company and Audit Committee. Similarly, shareholders will abstain from voting on any resolution presented to shareholders with respect to a transaction for which they are a related party.”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Parties“Certain types of transactions with related parties do not require approval under this policy, such as the employment or compensation of executive officers or directors and transactions where the related party’s interest arises solely from ownership in our securities and all shareholders receive proportional benefits.”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Parties“In determining whether to approve a related party transaction, the Audit Committee, Board of Directors, or shareholders, as applicable, should consider the material facts and relevant factors, including the following:”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Parties“whether the terms and conditions are fair and on an arm’s length basis and are in the ordinary course;”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Parties“whether there are appropriate business reasons for entering into the transaction;”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Parties“whether the transaction is on terms no less favorable than those that could have been reached with an unrelated party;”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Parties“the potential for the transaction to affect the independence of an independent director or lead to reputational risk or an actual or apparent conflict of interest for our executive officers or directors; and • any other information regarding the transaction or the related party that would be material to investors in light of the circumstances of the particular transaction.”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Parties“The related party transaction should only be approved if it is determined to be consistent with the interests of the Company and its shareholders. If a related party transaction is ongoing, the Audit Committee may establish guidelines for management to follow in its ongoing dealings with the related party and may periodically review and assess such ongoing transaction to determine whether it remains fair and reasonable to the Company.”
Read it in the proxyopen_in_new
Transactions with Related Persons“In January 2025, the Company entered into a license agreement with Zenas BioPharma (HK) Limited, a subsidiary of Zenas BioPharma, Inc. (“Zenas”), pursuant to which the Company obtained a license under certain patents and know-how of Zenas to develop and commercialize products containing a differentiated humanized monoclonal antibody targeting IGF-1R as an active ingredient in Greater China. One of the members of the Company’s Board of Directors, Mr. Moulder, is also the Chief Executive Officer and Chairman of the Board of Directors of Zenas. Since January 2025, the Company has paid a $10.0 million upfront fee in accordance with this agreement. As of March 31, 2026, the Company may be required to pay an additional aggregate amount of up to $117.0 million in development and sales-based milestones as well as certain royalties at tiered percentage rates ranging from high-single digits to mid-teens on annual net sales of the licensed products in the licensed territories. The related party arrangement with Zenas was approved by the Board of Directors in accordance with our related party transaction policy, excluding Mr. Moulder pursuant to our conflicts of interest policy. This related party transaction is not a connected transaction under Chapter 14A of the HK Listing Rules.”
Read it in the proxyopen_in_new
Indemnification“Cayman law does not limit the extent to which a company’s articles of association may provide indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as providing indemnification against civil fraud or the consequences of committing a crime. Our Current Articles provide that each director and officer shall be indemnified and secured harmless out of the assets and funds of our Company against all actions, proceedings, costs, charges, expenses, losses, damages, or liabilities incurred or sustained by him or her in connection with the execution or discharge of his or her duties, powers, authorities, or discretion as a director or officer of our Company, including without prejudice to the generality of the foregoing, any costs, expenses, losses, or liabilities incurred by him or her in defending (whether successfully or otherwise) any civil proceedings concerning the Company or its affairs in any court whether in the Cayman Islands or elsewhere.”
Read it in the proxyopen_in_new
Indemnification“We have entered into indemnification agreements to indemnify our directors and executive officers that will provide such persons with additional indemnification beyond that provided in our Current Articles. These agreements, among other things, indemnify our directors and executive officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being such a director or executive officer.”
Read it in the proxyopen_in_new
Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗
Sources
The related-party section (Item 404) of the latest annual proxy statement (DEF 14A), against last year's, compared by their words.
Also
CEO pay: the same proxy's pay versus performance table.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ZLAB/export.csv") into a cell.